In this interview, Prof. Srdan Verstovsek, MD, PhD, from the MD Anderson Cancer Center, Houston, TX, suggests that various parameters should be considered when monitoring patients before they progress to acute myeloid leukemia (AML), such as anemia and fibrosis. From the 2018 Society of Hematologic Oncology (SOHO) in Houston, TX, Prof. Verstovsek emphasises that genetic abnormalities can be detected in healthy people without the disease, so various other factors such as the bone marrow environment should be considered when making informed diagnostic and therapeutic decisions of myeloproliferative disorders.
Genetic abnormalities for detecting patients at risk of AML
